Junshi Biosciences announces submission of a marketing authorisation application to the European Medicines Agency for toripalimab

Junshi Biosciences

14 November 2022 - The MAA was submitted in the EU for toripalimab seeking indications for the first-line treatment of NPC and the first-line treatment of ESCC.

Shanghai Junshi Biosciences announced today that the company has submitted a marketing authorisation application to the European Medicines Agency for toripalimab.

Read Junshi Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Europe , Dossier